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The objective of the study was to compare responses of pigs vaccinated with a PRRS MLV vaccine against
PRRSV-1 or PRRSV-2 with the responses of pigs vaccinated simultaneously with both vaccines.
Furthermore, the efficacy of the two PRRSV MLV vaccination strategies was assessed following challenge.
The experimental design included four groups of 4-weeks old SPF-pigs. On day 0 (DPV0), groups 1–3
(N = 18 per group) were vaccinated with modified live virus vaccines (MLV) containing PRRSV-1 virus
(VAC-T1), PRRSV-2 virus (VAC-T2) or both (VAC-T1T2). One group was left unvaccinated (N = 12). On
DPV 62, the pigs from groups 1–4 were mingled in new groups and challenged (DPC 0) with PRRSV-1,
subtype 1, PRRSV-1, subtype 2 or PRRSV-2. On DPC 13/14 all pigs were necropsied. Samples were col-
lected after vaccination and challenge. PRRSV was detected in all vaccinated pigs and the majority of
the pigs were positive until DPV 28, but few of the pigs were still viremic 62 days after vaccination.
Virus was detected in nasal swabs until DPV 7–14. No overt clinical signs were observed after challenge.
PRRSV-2 vaccination resulted in a clear reduction in viral load in serum after PRRSV-2 challenge, whereas
there was limited effect on the viral load in serum following challenge with the PRRSV-1 strains.
Vaccination against PRRSV-1 had less impact on viremia following challenge. The protective effects of
simultaneous vaccination with PRRSV Type 1 and 2 MLV vaccines and single PRRS MLV vaccination were
comparable. None of the vaccines decreased the viral load in the lungs at necropsy. In conclusion, simul-
taneous vaccination with MLV vaccines containing PRRSV-1 and PRRSV-2 elicited responses comparable
to single vaccination and the commercial PRRSV vaccines protected only partially against challenge with
heterologous strains. Thus, simultaneous administration of the two vaccines is an option in herds with
both PRRSV types.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is one of
the most devastating infections in most swine producing countries
globally. In the US, the annual losses due to PRRS reach $644 mil-
lion annually [1] and the losses after an acute outbreak has been
estimated to be between 59 and 379 Euro/sow in Holland [2].
Therefore, huge efforts are put into the elimination and control
of the PRRS virus (PRRSV). Due to horizontal transmission of PRRSV
[3], the risk of PRRSV infection is high in swine dense areas and
therefore the strategy employed in most farms in Denmark and
other parts of Europe is to establish a PRRS stable sow herd where
sows are PRRSV antibody positive and PRRS virus negative and
wean PRRSV free pigs. PRRSV vaccines are commonly used to
immunize young breeding animals before introduction to the
sow herd.
Both Modified Live Virus (MLV) vaccines and killed vaccines are
available, but the efficacy of killed PRRS vaccines in stimulating
protective immunity is questionable [4] and therefore MLV
vaccines are used in most herds. Several studies have shown good
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efficiency of MLV against challenge with related strains [5]. Some
studies also found partial protection against challenge with more
divergent strains, whereas others found a poor cross-protection
of vaccines containing more divergent strains [reviewed in 5].
These apparent differences in outcome of different experiments
are probably due to the different experimental designs, different
vaccines used, different challenge strains, different breeds, age of
the animals, challenge dose etc. Nevertheless, it is generally
accepted that the degree of protection elicited by PRRSV vaccines
are related to the level of genetic and antigenic similarity between
the challenge and vaccine strain, even though that the level of
genetic and antigenic similarity is not necessarily predictive of pro-
tection [6].
Both PRRSV-1, subtype 1 and PRRSV-2 are circulating and caus-
ing disease in some European countries [7,8]. In contrast, PRRSV-1
strains belonging to subtypes 2, 3, and 4 have never been detected
in Western Europe [23]. In Denmark, it is common that pigs are
simultaneously vaccinated with two different PRRS MLV vaccines
containing PRRSV-1 and PRRSV-2. There is limited published data
on the impact on duration of viremia, immune responses and effi-
cacy after administration of two PRRS MLV vaccines containing
PRRSV-1 and PRRSV-2 at the same time [9].
The objective of the study was therefore to compare the safety
and efficacy of single PRRS MLV vaccinated pigs with responses in
pigs simultaneous vaccinated with PRRSV Type 1 and 2 vaccines.
2. Materials and methods
2.1. Experimental design
In total, 66 four-week-old PRRSV-negative pigs were included in
the study. The pigs were purchased from a specific pathogen-free
herd and tested free of a range of pathogens including PRRSV,
swine influenza A virus, Actinobacillus pleuropneumoniae (AP) and
Mycoplasma hyopneumoniae by serology prior to the study. The
pigs also tested negative by real-time PCR for Porcine circovirus
type 2 (PCV2) virus at arrival. The pigs were housed at the exper-
imental animal facilities at the National Veterinary Institute under
appropriate biosecurity conditions. On arrival, the pigs were ran-
domly allocated into four groups housed in separate rooms.
One week after arrival (0 days post vaccination, DPV 0), the pigs
in groups 1–3 (N = 16) were vaccinated with either Porcilis PRRS
VET (MSD Animal Health, Denmark) containing PRRSV-1 (VAC-T1),
Ingelvac PRRS VET (Boehringer Ingelheim Animal Health, Den-
mark) containing PRRSV-2 (VAC-T2) or both vaccines simultane-
ously (VAC-T1T2) (Table 1). Porcilis PRRS VET was
administrated with 2 mL at the left side of the neck and Ingelvac
PRRS VET administrated with 2 mL at the right side of the neck.
Nine weeks after vaccination (DPV 62), all pigs were moved to
new separated groups according to the PRRSV strain they were
planned to be challenged with (Table 1). The challenge was done
with either PRRSV-1, subtype 1 (strain 18794 [10]), PRRSV-2
(strain 19407b) or PRRSV-1 subtype 2 (strain ILI6 [10]) according
to Table 1. The PRRS-19407B had been isolated in January 1997
from the lungs of a stillborn pig. This pig originated from a swine
herd with a sudden high occurrence of stillborn pigs and increased
piglet mortality in the nursing period, consistent with an acute
outbreak of PRRS. The following day (0 days post challenge (DPC
0), corresponding to DPV 63), all pigs were inoculated intranasally
by placing the pigs on their buttocks perpendicular to the floor and
expanding the neck fully. The inoculum was slowly dripped into
the nostrils (2 mL/nostril) of the pigs taking approximately 3–5
min/pig.
The PRRSV-1, subtype 1 inoculum contained 5  105 culture
infective dose (TCID50)/mL) of PRRSV (passage 6, PAM, 1 mL virus
suspension in 3 mL MEM). The PRRSV-2 inoculum contained
5  105 TCID50/mL of PRRSV (passage 3, Marc-145, 1 mL virus sus-
pension in 3 mL MEM) and the PRRSV-1, subtype 2 inoculum con-
tained 3.7  105 TCID50/mL.
The study was carried out in accordance and permission grated
by the Danish legislation on animal experiments (LBK nr 1306 –
23/11/2007; permission number 2014–15–0201–00091) and EU
regulations on the use of laboratory animals for research.
2.2. Sampling
Blood samples were collected on days 2, 6, 14, 21, 28, 35, 42, 49,
56 and 62 DPV from vaccinated pigs and on day 62 for non-
vaccinated control pigs (NON-VAC). Blood samples were also col-
lected on days 1, 3, 5, 9 and 13 after challenge (DPC). Serum was
separated from the blood and stored at 80 C until test. Nasal
swabs were collected on DPV 1, 2, 5, 14, and 21 and DPC 1, 3, 4,
5, and 9. The swabs were collected in 1 mL PBS and stored at
80 C until test.
2.3. Clinical observation
A clinical score was assessed daily based on general health con-
dition (normal, mild lethargic, lethargic or apathetic), respiration
(normal, increased respiration, respiratory distress, severe respira-
tory distress), and appetite (normal, slow eating, not eating). Rectal
Table 1
Experimental design. The pigs were allocated to three vaccination groups vaccinated with MLV vaccines containing PRRSV-1 (VAC-T1), PRRSV-2 (VAC-T2) or both (VAC-T1T2).
Each of the vaccination groups were split into three different groups prior to challenge. The NON-VAC group was kept as unvaccinated control group. *Four pigs died prior to
challenge and one pig was excluded due to lack of seroconversion after vaccination resulting in a lower number of pigs in some of the challenge groups (4 or 5 pigs per group
instead of 6 pigs).
Group No. pigs PRRSV vaccination PRRSV challenge
VAC-T1 18* PorcilisPRRS VET 5* pigs PRRSV-1 subtype 1
5* pigs PRRSV-2
5* pigs PRRSV-1 subtype 2
VAC-T2 18 IngelvacPRRS VET 6 pigs PRRSV-1 subtype 1
6 pigs PRRSV-2
6 pigs PRRSV-1 subtype 2
VAC-T1T2 18* PorcilisPRRS VET + 6 pigs PRRSV-1 subtype 1
IngelvacPRRS VET 6 pigs PRRSV-2
4* pigs PRRSV-1 subtype 2
NON-VAC 12 No vaccination 4 pigs PRRSV-1 subtype 1
4 pigs PRRSV-2
4 pigs PRRSV-1 subtype 2
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temperature was recorded on days 1, 0, 2, 5, and 6 DPV and 1, 2,
3, 4, 5, and 6 DPC.
2.4. Necropsy
Of practical reasons half of the animals in each group was
necropsied on each day on DPCs 13 and 14, respectively. The pigs
were euthanized using a captive bolt immediately followed by a
cut of A. axillaris. A gross pathological examination was performed.
Lung pieces from the right and left caudal lobes and the right apical
lobe were collected from all pigs and pooled in the same tube.
From lungs with macroscopic lesions, a tissue section was collected
from the affected area and stored in a separate tube. The tissue
samples were stored at 80 C until use.
2.5. Laboratory methods
2.5.1. RNA extraction and RT-qPCR assays
Total RNA was extracted from serum, nasal swabs and lung
samples as previously described [10]. Known PRRSV positive sam-
ples and negative controls were included for at least each batch of
10 samples. Extracted RNA was stored at 80 C.
A recent designed assay was used for the real-time RT-qPCR
analyses [10]. The assay was designed specifically to detect
PRRSV-1 subtype 1 and subtype 2 strains used in this study. The
primers and probe target ORF2. For detection of PRRSV-2, the pre-
viously published RT-qPCR ‘‘Kleiboeker mod-1” primers and probe
targeting ORF7 3’UTR were used [11].
2.5.2. Conventional PCR and sequencing
The conventional PCR amplifications of ORF5 and ORF7 and the
sequencing were performed as previously described for PRRSV-2
[8]. For the sequencing of PRRSV-1, subtype 1 and subtype 2,
amplification of ORF5-ORF6 was performed using a ORF5-fw and
a ORF6-Rev primer [12] resulting in a PCR fragment of 1288 bp.
PCR and sequencing primers were the same. Only ORF5 sequences
were included in the analysis. The sequencing of PRRSV-1 ORF7 for
confirmation of some RT-PCR results was performed as earlier
described [7].
2.5.3. C-reactive protein (CRP)
Acute phase proteins (APPs) are inducted in response to infec-
tion and because measurable clinical signs are difficult to induce
in pigs with PRRSV, measurement of the porcine APP CRP was
included as an ‘‘objective” measure of infection. CRP was analyzed
by a sandwich type ELISA using dendrimer-coupled cytidine
diphosphocholine (a CRP-binding ligand) in the coating layer as
earlier described employing polyclonal rabbit anti-human antibod-
ies with cross-reactivity towards porcine CRP followed by
peroxidase-conjugated goat anti rabbit antibody for detection
(both antibodies from DAKO, Glostrup, Denmark) [13]. The lower
limit of quantification of the assay was 780 ng/ml.
2.6. Laboratory analyses
All serum and nasal swab samples collected at 2, 6, 14, 21, 28,
35, 42, and 62 DPV from vaccinated pigs were tested in real-time
RT-PCR. Samples from VAC-T1 and VAC-T1T2 pigs were tested in
the real-time RT-PCR for PRRSV-1 and samples from VAC-T2 and
VAC-T1T2 pigs in the real-time RT-PCR specific for PRRSV-2.
Samples from VAC-T1 and VAC-T2 pigs, that were negative at 42
DPV in real-time RT-PCR, were not tested day 49 and 56. Samples
from VAC-T1T2 pigs negative for both PRRSV-1 and PRRSV-2 at 42
DPV in real-time RT-PCR, were not tested DPV 49 and 56. All other
samples from VAC-T1, VAC-T2 and VAC-T1T2 were tested DPV 49
and 56.
From samples positive in real-time RT-PCR at DPV 62, a new
RNA extraction was performed from the original sample and tested
again in real-time RT-PCR. If the real-time RT-PCR was positive, a
conventional PCR targeting ORF7 was performed and the PCR pro-
duct confirmed by sequencing. All samples from NON-VAC pigs
were tested in real-time RT-PCR for both PRRSV-1 and PRRSV-2
at DPC-1.
Following challenge, nasal swabs and serum collected 1, 3, 5, 9,
and 13 DPC were tested in real-time RT-PCR specific for the chal-
lenge strain. Serum from the same days was tested for CRP.
The three lung pieces collected from each pig at necropsy were
pooled and tested by real-time RT-PCRs specific for the challenge
strain and the PRRSV virus species used for vaccination. ORF5 of
the virus RNA detected in the lungs of one pig from each group
was sequenced as described above.
2.7. Statistical analysis
The binary response of PCR positive pigs after vaccination were
analyzed separately, for PCR PRRSV-1 (VAC-T1 against VAC-T1T2)
and for PCR PRRSV-2 (VAC-T2 against VAC-T1T2). The analyses
were performed using the GLIMMIX procedure with logit as link
function and including vaccine and time as a fixed effect and with
the repeated measurement on the same pig during time, having a
AR(1) covariance structure. The statistical package SAS version 9.2
(SAS institute Inc., Cary, NC, USA) was used. A value of P < .05 was
considered significant. Group sample sizes of 18 and 18 achieve
81% power to detect an odds ratio of 0.286 in a design with 9
repeated measurements having a AR(1) covariance structure when
the proportion from group 2 is 0.600, the correlation between
observations on the same subject is 0.680, and the alpha level is
0.050.
3. Results
3.1. Limited clinical signs observed after vaccination and challenge
No respiratory clinical symptoms were observed after vaccina-
tion. Four pigs were suffering from diarrhea and were euthanized
due to poor body condition (three VAC-T1 pigs at 14, 23, and 23
DPV, one VAC-T1T2 pig at 37 DPV).
Several of the vaccinated pigs that were challenged with PRRSV-
1, subtype 2, got a clinical score at DPC 5; one VAC-T1T2 pig was
lethargic and was not eating; two VAC-T1 pigs, three VAC-T2 pigs
and one VAC-T1T2 pig were mildly lethargic. None of the pigs chal-
lenged with PRRSV-1, subtype 1 or PRRSV-2 developed clinical
signs after challenge. Some animals experienced a slight increase
in rectal temperature at DPC 3, however none of the pigs developed
fever as defined as rectal temperature above 40.5 C (data not
shown).
3.2. Acute phase protein responses were induced in response to
challenge
All pre-challenge serum concentrations of CRP were below 10
lg/ml which generally is regarded as the upper cut-off for healthy
animals [14] (Fig. 1). After challenge, PRRSV-1, subtype 1 and
PRRSV-2 induced similar patterns of elevated CRP concentrations
peaking at 1 DPC while the PRRSV-1, subtype 2 strain induced a
slower and more protracted response with elevated CRP concen-
trations found at 1 and 5 DPC and, although less pronounced, at
9 DPC.
The CRP responses of the different vaccinated groups and the
unvaccinated controls were striking in that the group vaccinated
with both vaccines consistently had the highest number of samples
C.S. Kristensen et al. / Vaccine 36 (2018) 227–236 229
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Fig. 1. C-reactive protein (CRP) responses to PRRSV challenge in vaccinated and unvaccinated pigs. Level of CRP (ng/ML) were measured in animals challenge with a PRRSV-1,
subtype 1 strain (top), a PRRSV-2 strain (center) or a PRRSV-1, subtype 2 strain (bottom) at day -14, 1, 5, 9, and 13 after challenge (DPC). Groups of pigs were vaccinated with
MLV against PRRSV-1 (VAC-T1), PRRSV-2 (VAC-T2) or both (VAC-T1T2) 63 days prior to challenge.
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with CRP concentrations above 10 lg/ml, followed by the single
vaccinated groups and with the unvaccinated group consistently
having the fewest samples above the cut-off (Fig. 1).
3.3. PRRSV was detected for a prolonged time in serum following
vaccination
One VAC-T1T2 pig did not develop viremia after vaccination,
either because this animal was mistakenly not vaccinated or that
the pigs were unable to respond to vaccination. Based on this,
the pig was excluded from further analysis. The blood samples
from two VAC-T1 and all VAC-T1T2 pigs collected at 28 DPV were
accidentally lost after sampling and prior to analysis. Apart from
the pig mentioned above, all vaccinated pigs became viremic at
least one day following vaccination as measured by real-time RT-
PCR for PRRSV-1 and/or PRRSV-2 according to the vaccine used
(Fig. 2).
Following vaccination, the VAC-T1 and VAC-T1T2 pigs had the
lowest mean Ct value in serum. None of the VAC-T1T2 pigs were
positive after DPV 42, whereas two VAC-T1 pigs remained weakly
positive at 62 DPV (Fig. 2). Sequencing of ORF5 from these samples
confirmed that they were vaccine virus positive. No significant dif-
ferences were found comparing the proportion of positive pigs
between the VAC-T1 and VAC-T1T2 groups of pigs (p = .21), but
the level of virus RNA in serum of VAC-T1T2 pigs tended to be
higher than in the VAC-T1 pigs.
The majority of pigs vaccinated with the PRRSV-2 vaccine
(VAC-T2 and VAC-T1T2) were positive for PRRSV-2 viral RNA in
serum from DPV 6 to DPV 28 (Fig. 2), however, one VAC-T1T2
pig did not become positive until DPV 42. Eight VAC-T2 and three
VAC-T1T2 pigs tested positive also at DPV 42 and two VAC-T2 pigs
were still weakly positive at DPV 62 (Fig. 2). Sequencing of ORF5
from these samples confirmed that they were PRRSV vaccine virus
positive. Overall, the number of PRRSV-2 serum positive pigs was
higher in the VAC-T2 group compared to the VAC-T1T2 group (p
= .007) (Fig. 2). Overall, the level of virus RNA in serum of VAC-
T1T2 pigs was not different from the VAC-T2 pigs.
The highest proportion of nose swabs positive in real-time RT-
PCR was seen at 5 DPV where 5–7 pigs in each group were positive
(Table 2). At DPC 14, only one VAC-T1 and three VAC-T1T2 pigs
tested positive for PRRSV-1, whereas none of the pigs were positive
for PRRSV-2. At DPV 21 all nose swabs were negative (Table 2).
3.4. PRRSV were detected in sera and nasal swabs following challenge
of vaccinated pigs
After challenge with PRRSV-1, subtype 1, all vaccinated pigs
were positive in serum at minimum one time-point when tested
by the real-time RT-PCR specific for PRRSV-1. All NON-VAC pigs
were viremic at all sampling dates (Fig. 3). The level of virus in
the NON-VAC group was in general higher than in the vaccinated
groups. Overall, development of viremia was delayed and of
shorter duration in the vaccinated pigs and all PRRSV-1 vaccinated
pigs (VAC-T1 and VAC-T1T2) were negative in serum at DPC 13.
Interestingly, two of the VAC-T2 pigs that tested negative at DPC
9 became positive again on DPC 13. To confirm these results the
RT-PCR tests were repeated on new RNA extractions with similar
results.
In nasal swabs, only two out of five pigs vaccinated and chal-
lenged with PRRSV-1, subtype 1 were positive and only at one
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Fig. 2. Viral load expressed as mean Ct values and the number of positive pigs (N) in serum after vaccination with MLV against PRRSV-1 (VAC-T1), PRRSV-2 (VAC-T2) or both
(VAC-T1T2). The serum samples were tested with an RT-PCR assay specific for PRRSV-1 (top) or PRRSV-2 (bottom). Samples with Ct values above 40 were considered negative.
DPV = days post vaccination.
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sampling (DPC 9) whereas 4 and 2 pigs out of 6 double vaccinated
pigs were positive at DPC 4 and 5, respectively. Out of the four
unvaccinated pigs challenged with PRRSV-1, subtype 1, two-
three were positive in nasal swabs at DPC 3–9, which were similar
to the pigs vaccinated with PRRSV-2 apart from no positive pigs
were seen in this group at DPC 9 (Table 2).
The challenge with PRRSV-2 resulted in only one positive VAC-
T2 pig and one positive VAC-T1T2 pig in serum the day after chal-
lenge (DPC 1) (Fig. 3). At all other samplings, all VAC-T2 and VAC-
T1T2 pigs tested negative for PRRSV-2. All NON-VAC pigs were pos-
itive for Type 2 PRRSV at all sampling days. The VAC-T1 pigs were
positive for PRRSV-2 at DPC 1, 3, and 5, became negative at DPC 9
and then became positive again at DPC 13 (Fig. 3). To confirm these
results the real-time RT-PCR tests were repeated on new RNA
extraction with similar results.
Of the 12 pigs vaccinated and challenged with PRRSV-2, only
one pig was positive in nasal swabs (at DPC 5) (Table 2). In the
unvaccinated control group, only 1 of 4 pigs was positive at DPCs
1, 3, and 4, whereas 3 were positive at DPC 5. Interestingly, nasal
shedding of PRRSV were more pronounced in pigs vaccinated with
a vaccine containing PRRSV-1 in that 4–5 of the pigs were positive
at DPC 3–5 (Table 2).
Following challenge with PRRSV-1, subtype 2, all pigs apart
from two pigs in the VAC-T1T2 group were viremic at DPVs 3, 5,
and 9 when tested in real-time RT-PCR specific for PRRSV-1, sub-
type 2 (Fig. 3). One of the VAC-T1T2 pigs did not respond until 5
DPC, where the first VAC-T1T2 pig became negative again. The
mean Ct-value were comparable among the four groups, but vacci-
nated animals had in general higher Ct values compared to the
unvaccinated control pigs especially at the later sampling days
(Fig. 3).
PRRSV was detected in nasal swabs in all groups at DPCs 3–9
and the numbers of positive pigs were equal to or higher in the
vaccinated groups compared to the unvaccinated controls
(Table 2).
3.5. Challenge induced limited macroscopic changes
All pigs had increased size of Lnn Bronchiales, apart from 8 of
the 17 VAC-T2 pigs (five challenged with PRRSV-1, subtype 1;
one challenged with PRRSV-2 and one challenged with PRRSV-1,
subtype 2) and two of the 15 VAC-T1 pigs (challenged with
PRRSV-1, subtype 1). Following challenged with PRRSV-2, three
NON-VAC pigs had intestinal pneumonia and one NON-VAC pig
showed signs of bronchopneumonia.
3.6. Vaccination had limited effect on PRRSV load in the lungs after
challenge
One out of five pigs vaccinated and challenged with PRRSV-1,
subtype 1, two out of five pigs vaccinated and challenge with
PRRSV-2, three out of six pigs vaccinated with both vaccines and
challenged with PRRSV-1, subtype 2 and four out of six pigs vacci-
nated with both vaccines and challenged with PRRSV-2 were neg-
ative for PRRSV in lungs when tested by real-time RT-PCR. All
remaining pigs were positive for PRRSV in the lungs, including lung
samples collected from affected areas. Vaccinated pigs had levels of
virus in the lungs comparable to the control pigs when the load in
the predetermined lung samples were analyzed, excluding the
extra samples taken from affected areas (Fig. 4).
3.7. Sequencing of the challenge isolates
Sequencing of the ORF5 of the challenge strains, revealed a high
level of identity (98.7% nt homology) between the PRRSV-2 chal-
lenge strain and the PRRSV-2 vaccine strain (Table 3). In contrast,
the diversity between the PRRSV-2 vaccine strain and the PRRSV-
1, subtype 1 and PRRSV-1, subtype 2 challenge strains were
approximately 60%. The PRRSV-1 vaccine strain were 92, 82 and
62% identical to the PRRSV-1, subtype 1, PRRSV-1, subtype 2 and
the PRRSV-2 challenge strains, respectively (Table 3).
Sequence analysis of ORF5 of the virus isolated from the lungs
of one pig from each of the challenge groups were in all cases iden-
tical to the challenge strain (data not shown).
4. Discussion
The present study assessed the safety and efficacy of simultane-
ous administration of modified live vaccines containing attenuated
PRRSV-1 and PRRSV-2 viruses, respectively. None of the vaccinated
animals experienced any adverse effect following vaccination and
comparable levels of virus were seen following the two vaccination
strategies. Furthermore, no clear differences in responses were
seen after challenge between animals vaccinated with one or two
vaccines. Taken together, these results suggested that the safety
and efficacy of two PRRSV MLV vaccines given simultaneously
are similar to the safety and efficacy of the vaccines given alone.
Table 2
Number of pigs found positive in nasal swaps when tested in real-time RT-PCR assays specific for either type 1 or type 2 PRRSV following vaccination (top) with PRRSV-1 (VAC-
T1), PRRSV-2 (VAC-T2) or both (VAC-T1T2) and after challenge (bottom). DPV = days post vaccination. DPC = days post challenge. *One VAC-T1T2 vaccinated pig was excluded
from the study due to lack of seroconversion and three VAC-T1 and one VAC-T1T2 pig died prior to challenge.
DPV PRRSV-1 RT-PCR PRRSV-2 RT-PCR
VAC-T1 VACT1T2 VAC-T2 VACC-T1T2
N = 18* N = 17* N = 18 N = 17*
1 0 0 1 0
2 0 2 1 2
5 5 5 7 5
14 1 3 0 0
21 0 0 0 0
PRRSV 1-subtype 1 challenge PRRSV-2 challenge PRRSV 1-subtype 2 challenge
Vaccine DPC VAC-T1 VAC-T2 VAC-T1T2 Controls VAC-T1 VAC-T2 VAC-T1T2 Controls VAC-T1 VAC-T2 VAC-T1 T2 Controls
N = 5* N = 6 N = 6 N = 4* N = 5* N = 6 N = 6 N = 4 N = 5 N = 6 N = 4* N = 4
1 0 0 0 0 0 0 0 1 0 2 0 0
3 0 2 0 2 4 0 0 1 1 4 2 2
4 0 3 4 3 4 0 0 1 5 6 3 3
5 0 3 2 3 5 0 1 3 4 4 4 4
9 2 0 0 2 0 0 0 0 2 2 2 3
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Following vaccination, the only statistical difference encountered
was that the number of PRRSV-2 serum positive pigs overall were
higher in the group vaccinated with PRRSV-2 compared to the
group vaccinated with both vaccines (p = .007), whereas the serum
virus concentration was similar. The reason for this difference in
response is not clear since the immune system is normally able
to mount responses to several pathogens simultaneously. Further-
more, there was no clear difference between pigs vaccinated with
PRRSV-1 and pigs vaccinated with both vaccines in the response to
challenge with PRRSV-2. There are very few published studies on
simultaneous vaccination with different PRRSV vaccines. Park
and co-workers found that simultaneous vaccination with two vac-
cines against PRRSV-1 and PRRSV-2 and single vaccination were
equally effective in reducing PRRSV viremia and lung lesions fol-
lowing PRRSV-1 challenge whereas simultaneous vaccination had
limited effect on viremia and lung lesions following challenge with
PRRSV-2 [9]. This finding is in contrast to our findings and another
study by the same group that showed protection against the same
challenge strain in single vaccinated pigs [15]. The differences in
outcome between the studies may be that Park et al. used another
PRRSV-2 vaccine (Fostera PRRSV), a different challenge strain and
the duration between vaccination and challenge was 35 days com-
pared to the 62 days used in the present study. Furthermore, a
more recent study showed that vaccination of boars with vaccines
against PRRSV-1 and PRRSV-2 significantly reduced seminal shed-
ding following challenge with the same PRRSV-2 strain [16].
Virus could be detected in serum of several pigs at DPC 42–56,
and four (two VAC-T1 and two VAC-T2) pigs tested positive up to
62 days after vaccination. Previous studies have estimated the
length of viremia after PRRSV vaccination with MLV vaccines to
be 29 days on average (range 10–42 days) [12,17–20], but PRRSV
viral RNA has been detected in tonsil scrapings up to 90 days post
vaccination [20]. The different studies used different methods to
investigate the presence of virus in serum, which may account
for the differences seen. The sensitivity of different RT-PCR assays
varies considerably and is dependent on a wide range of factors.
One crucial determinant of sensitivity is the level of identity
between the primer and probe sequences and the isolate to be
tested [11]. In order to optimize the sensitivity of the virus detec-
tion assays employed, we chose to test for virus by real-time RT-
PCR assays that were specifically validated and optimized to recog-
nize the vaccine and challenge strains used in the present study.
Therefore, optimized sensitivity of the assays employed may
explain the long duration of viremia observed in our study com-
pared to the majority of the previous studies. It cannot be ruled
out that there was mutations in the probe and primer sites during
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Fig. 3. Viral load expressed as Ct values in serum after challenge with PRRSV-1,
subtype 1 (top), PRRSV-2 (center) or PRRSV-1, subtype 2 (bottom). Groups of pigs
were either unvaccinated or vaccinated with MLV against PRRSV-1 (VAC-T1),
PRRSV-2 (VAC-T2) or both (VAC-T1T2) 63 days prior to challenge. The serum
samples were tested with real-time RT-PCR assays specific for the challenge strain.
Samples with Ct values above 40 were considered negative. DPC = days post
challenge.
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Fig. 4. Viral load expressed as Ct values in the lungs after challenge with PRRSV-1,
subtype 1, PRRSV-2 or PRRSV-1, subtype 2. Groups of pigs were either unvaccinated
or vaccinated with MLV against PRRSV-1 (VAC-T1), PRRSV-2 (VAC-T2) or both
(VAC-T1T2) 63 days prior to challenge. The serum samples were tested with real-
time RT-PCR assays specific for the challenge strain. Samples with Ct values above
40 was considered negative.
Table 3
Level of identity (nucleotide identity expressed as % identity in ORF5) among the
vaccine and challenge strains used in the study.
Vaccine Challenge strain Type/subtype Identity (% nt)
PorcilisPRRS VET 18794 PRRSV-1, subtype 1 91.6
PorcilisPRRS VET ILI6 PRRSV-1, subtype 2 81.7
PorcilisPRRS VET 19407b PRRSV-2 62.3
IngelvacPRRS VET 18794 PRRSV-1, subtype 1 61.2
IngelvacPRRS VET ILI6 PRRSV-1, subtype 2 60.7
IngelvacPRRS VET 19407b PRRSV-2 98.7
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the replication in the pigs that would impair the sensitivity of the
PCR, however, there was no indications that this happened in the
present study. Another limitation of the study was that we stopped
testing of samples after the first day they became negative
excluded the possibility to detect a rebound of viremia – i.e. an ani-
mal that become positive after being tested negative. The duration
of nasal excretion of PRRSV was in line with the previous studies
quoted above (7–14 DPC). There is probably a limited risk that
these weakly positive animals would transmit the virus horizon-
tally to naïve animals [21], but the persistence of vaccine virus
for two-three months after vaccination emphasize the importance
of keeping vaccinated animals isolated from naïve animals for a
sustained time period prior to mingling. Furthermore, vertical
transmission from vaccinated boars for an extended time period
after vaccination cannot be ruled out since the presence of virus
in serum and semen is correlated [22].
One pig vaccinated with both vaccines tested positive very late
(at DPV 56) and most likely this pig either had a delayed response
to the vaccination or did not respond to vaccination at all and was
infected by litter mates excreting vaccine virus.
Three different PRRSV strains were used as challenge virus. In
West-European countries, circulating PRRSV-1, subtype 1 viruses
can be divided into two main clusters with one of the clusters
being highly similar to the PRRSV-1 reference strain LV (>95% iden-
tity in ORF 5), while some of the isolates from the other cluster dif-
fer more than 10% from the LV strain [7]. In the present study, the
PRRSV-1, subtype 1 strain 18794 was used as challenge strain. This
strain is an older Danish field isolate which share only 91.6% nt
identity in ORF5 with the PRRSV-1 vaccine strain and 81.7% iden-
tity with the PRRSV-1, subtype 2 challenge strain ILI6. The strain
ILI6 is a virus isolated in Russia in 2009 and belong to PRRSV-1,
subtype 2 [23]. This subtype has to our knowledge never been
detected in Western Europe [7].
Apart from sporadic detection of more diverse viruses in Hun-
gary [24], all known European PRRSV-2 field viruses belongs to
clade 5.1 and share high degree of identity to the PRRSV-2 vaccine
strain VR2332 [8]. The Danish field strain used as challenge strain
in the present study share 98.7% identity to the VR2332 strain. The
term ‘‘homologous” and ‘‘heterologous” PRRSV challenge are often
used to describe the degree of identity between PRRSV strains also
in vaccine trials, but the terms have not been uniformly defined. In
the present study it is reasonable to define the Type 2 challenge
strain as homologous to the PRRSV-2 vaccine strain and both
PRRSV-1 challenge strains to be heterologous to both vaccine
strains. Therefore the efficacy of the two vaccines cannot be
directly compared.
Few clinical signs were seen after challenge and only in the pigs
challenged with PRRSV-1 subtype 2. The pronounced CRP
responses seen on several sampling days, however, showed that
all the pigs indeed responded to the challenge, and the responses
were in accordance with previous results on the CRP response in
pigs after PRRSV challenge [14]. The post challenge CRP responses
and the clinical signs were more pronounced in vaccinated pigs,
and in particular in pigs vaccinated with both vaccines compared
to control pigs. The number of pigs included in each challenge
group was relatively low and combined with the rather marked
differences between the responses of pigs in the same group on
the CRP measurements it was not possible to make clear conclu-
sions on this, but these finding may indicate that the clinical signs
as well as subclinical reactions (CRP acute phase response) encoun-
tered in response to PRRSV infection may be immune mediated
[25].
In general, it is difficult to reproduce severe clinical signs in
experimental trials with European field isolates of PRRSV espe-
cially in older pigs [5]. Instead, the magnitude and duration of virus
in serum are often used as a correlate of protection in vaccination
trials. Pigs vaccinated against PRRSV-1 developed viremia shortly
after challenge with PRRSV-1 subtype 1, however, the pigs cleared
the virus from serum earlier than the other groups indicating par-
tial protection by the vaccine in response to the heterologous
PRRSV-1, subtype 1 virus challenge. There was no clear difference
between single and dual vaccinated pigs in the response to chal-
lenge with PRRSV-1 virus. Some studies have found similar incom-
plete effect of vaccination following challenge of PRRSV-1
vaccinated pigs with heterologous PRRSV-1 strains [17,26], while
others have found significant reduction in viremia following
PRRSV-1 vaccination in a quasi-natural experimental model [27]
and clinical protection in the field despite the field strain was only
85% identical to the vaccine strain in ORF 5 [19]. In the present
study, vaccination against PRRSV-1 did not protect against chal-
lenge with Type 2 virus which are in accordance with the majority
of previous studies [26,28–30]. The challenge in the present study
was performed approximately two months after vaccination which
is later than in most vaccine trials. The late challenge time was
chosen because the recommended quarantine lengths for Danish
gilts are minimum 8 weeks and we wanted to investigate if vaccine
virus was present in serum and nasal swabs for a prolonged time
after dual vaccination against PRRSV-1/PRRSV-2 compared to sin-
gle vaccination. The apparent lack of protection seen for some of
the groups may have been affected by this, but in a clinical setting
the vaccines should be able to protect animals after challenge two
months after vaccination. The limitation of using such a late chal-
lenge time was, however, that if was not possible to evaluate if the
onset of immunity has been altered by vaccination with both
vaccines.
PRRSV-2 vaccinated pigs were almost completely protected
from viremia following challenge with the homologous PRRSV-2
strain which is in accordance with previous studies with this vac-
cine [5,31–33]. In contrast, vaccination with the PRRSV-2 vaccine
had limited effect on viremia following challenge with PRRSV-1
which also is in accordance with the outcome of most of the previ-
ous comparable studies with this vaccine [5,26,34].
The challenge strain ILI6 belongs to PRRSV-1, subtype 2. PRRSV-
1, subtype 2 and subtype 3 viruses have only been detected east of
Poland and are more than 20% different from the PRRSV-1 subtype
1 strains circulating elsewhere [23]. Only few studies have been
performed with these diverse East-European strains, but a series
of studies have revealed that at least some subtype 3 strains are
more virulent than typical subtype 1 strains [35–38]. Recently,
we have shown that some subtype 2 strains seem to be more vir-
ulent than subtype 1 strains [10] and in both the previous and the
present study ILI6 induced more severe clinical signs and more
pronounced viremia than the PRRSV-1, subtype 1 strains. Never-
theless, the clinical signs were much less severe than seen follow-
ing challenge with the two subtype 3 strains SU-1 and Lena
[35,36]. Vaccination with PRRSV-1 and/or PRRSV-2 MLV vaccines
had minimal reducing effect on the viral load in serum and lungs
of ILI6 challenged pigs. Similarly, studies have shown that previous
infection or vaccination with PRRSV-1 subtype 1 strains provided
only partial protection against clinical signs and viremia following
challenge with the subtype 3 strain Lena [39–41]. More studies are
needed to investigate if the existing commercial vaccines will pro-
vide sufficient protection in the field against these diverse subtype
2–3 viruses.
Some of the pigs showed a biphasic trend in virus load in serum
in that they became positive at DPC 3–6, negative at DPC 9 and
then tested positive again at DPC 13. The retest of the samples con-
firmed the initial results. To our knowledge, this has not previously
been described in connection to PRRSV challenge and it is interest-
ingly that this trend only happened in vaccinated pigs challenged
with a heterologous strain of PRRSV. Furthermore, there was a
tendency that nasal shedding was more pronounced in vaccinated
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animals challenged with a heterologous strain - especially in single
vaccinated pigs challenge with ILI6. The underlining mechanisms
behind these observations remain speculative, but antibody-
dependent enhancement (ADE) has been shown to play a role in
the pathogenesis of PRRSV infection in pigs [42], thus more studies
on this is warranted.
5. Conclusion
None of the animals experienced any adverse effect following
single or simultaneous vaccination with two PRRSV MLV vaccines
and the viral load and duration of viremia were comparable
between the two groups. Furthermore, no differences in responses
of single and dual vaccinated animals were seen after homologous
and heterologous challenge. In conclusion, the safety and efficacy
of PRRSV MLV vaccines given simultaneously were similar to the
safety and efficacy of the vaccines given alone. This information
is very useful for decision making in swine herds situated in areas
where both PRRSV-1 and PRRSV-2 are circulating.
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